Northwest Biotherapeutics presented updated survival data for its DCVax-L therapy in glioblastoma at the British Neuro-Oncology Society meeting. Independent statisticians using individual patient data found the median survival benefit ranges from 3.4 to 6.3 months, significantly higher than the original 2.8 months estimate based on cohort data. These findings reinforce the therapy's potential to improve outcomes for this aggressive brain cancer. The company continues regulatory review and development of its personalized immunotherapy products.
Wedbush rang the closing bell at Cboe Global Markets to mark 18 years as a Cboe member, celebrating a partnership focused on innovation and market integrity. Since joining in 2008, Wedbush has supported the evolution of financial markets through new ...
The New Civil Liberties Alliance (NCLA) filed an appeal to revive a lawsuit against the Biden Administration and private companies for censoring social media posts by individuals injured by Covid vaccines. Plaintiffs, including vaccine-injured indivi...
Columbus Circle Capital Corp III announced the pricing of its initial public offering (IPO) of 20 million units at $10 each, raising $200 million. The units will begin trading on the Nasdaq Global Market under the symbol "CCCTU" on July 9, 2026. Each...
The global golf simulators market, valued at $2.4 billion in 2025, is projected to grow to $5.5 billion by 2035 at an 8.6% CAGR. Growth is fueled by technological improvements, increased commercial and residential use, and rising demand for indoor go...
Aimei Health Technology Co., Ltd. has terminated its business combination agreement with United Hydrogen Group Inc. due to failure to complete the merger by the agreed deadline. The termination was effective immediately as the closing did not occur b...
